Clinical Trial Update: Study of Continuous APL-1202 Treatment in Subjects With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Relapsed From Intravesical Chemo/BCG Therapy [Phase 2]

View source ↗

Summary

Phase 2 study of continuous APL-1202 in patients with high-risk non-muscle-invasive bladder cancer that relapsed after intravesical chemo/BCG therapy has comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• APL-1202 (APL-1202)

Snippet

Sponsor: Jiangsu Yahong Meditech Co., Ltd aka Asieris | Conditions: Non-muscle Invasive Bladder Cancer | Phase 2 | Status: COMPLETED